Spots Global Cancer Trial Database for fallopian tube cancer
Every month we try and update this database with for fallopian tube cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | NCT02824328 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Endomet... | 18 Years - | Duke University | ||
| Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients | NCT00478452 | Ovarian Cancer Fallopian Tube ... Primary Periton... | DC-Ova DC Ova with Cyc... | 18 Years - | University of Pennsylvania | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Determining Prognostic Immune Markers in Patients With Ovarian Cancer | NCT03862677 | Epithelial Ovar... | No intervention | 18 Years - | Leiden University Medical Center | |
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | NCT01649336 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | MEK162, MEK inh... Paclitaxel, mit... | 18 Years - | Array BioPharma | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer | NCT02480374 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | IMNN-001 | 18 Years - | Imunon | |
| A Survivorship Care Plan for Gynaecological Cancer Patients | NCT01582906 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | 18 Years - 60 Years | Royal Marsden NHS Foundation Trust | ||
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | NCT00390234 | Fallopian Tube ... Female Reproduc... Ovarian Carcino... Ovarian Sarcoma Recurrent Ovari... Recurrent Uteri... Stage III Ovari... Stage III Uteri... Stage IV Ovaria... Stage IV Uterin... Uterine Carcino... Uterine Leiomyo... | ziv-aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer | NCT03693248 | Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Peritoneal Canc... | Two cycles of n... | 20 Years - 80 Years | Seoul National University Hospital | |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | NCT03704467 | Ovarian Cancer | M6620 Avelumab Carboplatin | 18 Years - | EMD Serono | |
| Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT02278783 | Ovarian Cancer Primary Periton... Fallopian Tube ... | regorafenib | 18 Years - | University of Utah | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | NCT05769959 | Renal Cell Carc... Non-small Cell ... Pancreatic Aden... Colorectal Canc... Ovarian Neoplas... | RO7515629 tocilizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | NCT05417594 | Advanced Solid ... | AZD9574 Temozolomide [11C]AZ1419 339... Datopotamab Der... Trastuzumab Der... | 18 Years - 130 Years | AstraZeneca | |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | NCT02668913 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... Gynaecological ... | Diagnostic anal... | 18 Years - | University of Leeds | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | NCT04201561 | Chemotherapy-in... Recurrent Ovari... Ovarian Cancer Fallopian Tube ... Primary Periton... | sodium selenite... Normal saline Chemotherapy | 19 Years - 80 Years | Seoul National University Hospital | |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | NCT00856180 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Bevacizumab Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | NCT01188876 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin pralatrexate Folic Acid Vitamin B12 Inj... | 18 Years - | Massachusetts General Hospital | |
| A Study of Sovilnesib in Subjects With Ovarian Cancer | NCT06084416 | High Grade Sero... Fallopian Tube ... Primary Periton... Chromosomal Ins... | Sovilnesib | 18 Years - | Volastra Therapeutics, Inc. | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | NCT02661815 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Paclitaxel Ricolinostat Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | NCT00520013 | Ovarian Cancer Fallopian Tube ... Primary Periton... Papillary Serou... Clear Cell Mull... | bevacizumab erlotinib paclitaxel carboplatin | 18 Years - | Dana-Farber Cancer Institute | |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | NCT01610206 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Gemcitabine pazopanib | 18 Years - | University of Virginia | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | NCT05065021 | Ovarian Cancer Fallopian Tube ... Primary Periton... High Grade Sero... High Grade Endo... | Niraparib Dostarlimab Bevacizumab Paclitaxel | 18 Years - | University Health Network, Toronto | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | NCT04701645 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Fallopian Tube ... | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT03029403 | Advanced Cancer Ovarian Cancer Primary Periton... Fallopian Tube ... | Pembrolizumab DPX-Survivac Cyclophosphamid... | 18 Years - | University Health Network, Toronto | |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | NCT02725489 | Breast Cancer Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Endometrial Can... | Vigil Durvalumab | 18 Years - | Mary Crowley Medical Research Center | |
| Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | NCT01308944 | Invasive Epithe... Primary Periton... Fallopian Tube ... | Propranolol | 18 Years - | Washington University School of Medicine | |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | NCT00436215 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | NCT02859038 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Upfront cytored... Interval debulk... | 18 Years - | Shanghai Gynecologic Oncology Group | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology | NCT06184867 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Breast Cancer Pancreas Cancer Colorectal Canc... Endometrial Can... Prostate Cancer | Relational Agen... Clinical Letter | 18 Years - | Rutgers, The State University of New Jersey | |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | NCT00066651 | Cervical Cancer Fallopian Tube ... Head and Neck C... Lung Cancer Malignant Mesot... Ovarian Cancer Pancreatic Canc... Primary Periton... | SS1(dsFv)-PE38 ... | 18 Years - | National Cancer Institute (NCI) | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 | NCT04590326 | Ovarian Cancer Fallopian Tube ... Primary Periton... Endometrial Can... | REGN5668 Cemiplimab REGN4018 Sarilumab | 18 Years - | Regeneron Pharmaceuticals | |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR | NCT04295577 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Niraparib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | NCT00010179 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival | NCT04402333 | Ovarian Cancer Ovarian Neoplas... Ovarian Neoplas... Fallopian Tube ... Peritoneal Canc... | Robotic Interva... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT00753480 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | D4064A | 18 Years - | Genentech, Inc. | |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | NCT03924245 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... High Grade Fall... High Grade Ovar... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Primary Periton... Recurrent Endom... Recurrent Ovari... Recurrent Prima... | Entinostat Olaparib | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors | NCT05080946 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Aspirin 325mg Placebo | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Development and Management of Registry in Patients With Gynecologic Cancer in Korea | NCT05912972 | Cervical Cancer Endometrial Can... Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Patient registr... | 18 Years - | Asan Medical Center | |
| Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer | NCT05792254 | Primary Ovarian... Fallopian Tube ... Peritoneal Canc... | Huaier granule | 18 Years - | Ruijin Hospital | |
| Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer | NCT00287885 | Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... Sarcoma Vaginal Cancer Vulvar Cancer | docetaxel | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | NCT00012090 | Fallopian Tube ... Ovarian Cancer Primary Periton... | bicalutamide goserelin aceta... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| A Study of ZN-c3 in Patients With Ovarian Cancer | NCT04516447 | Solid Tumor Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | ZN-c3 Carboplatin Pegylated lipos... Paclitaxel Gemcitabine Bevacizumab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | NCT03740165 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Pembrolizumab Placebo for pem... Carboplatin Paclitaxel Olaparib Placebo for ola... Bevacizumab Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00041080 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | tamoxifen citra... thalidomide laboratory biom... | - | National Cancer Institute (NCI) | |
| Panitumumab and Gemcitabine in Relapsed Ovarian Cancer | NCT01296035 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Panitumumab | 18 Years - | Women and Infants Hospital of Rhode Island | |
| CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00096239 | Fallopian Tube ... Ovarian Cancer Primary Periton... | CP-547,632 | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | NCT01952249 | Primary Periton... | Demcizumab Taxol | 21 Years - 90 Years | Mereo BioPharma | |
| Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01670799 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Ketorolac | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study of Long-Term Responders on Olaparib | NCT02489058 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | 18 Years - | University Health Network, Toronto | ||
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | NCT03657043 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | tisotumab vedot... | 18 Years - | Seagen Inc. | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | NCT01100372 | Fallopian Tube ... Ovarian Cancer Primary Periton... | gemcitabine hyd... liposome-encaps... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | NCT02324439 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Omega Nutrition... | 21 Years - | Southern Illinois University | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care | NCT04368130 | Ovarian Cancer Fallopian Tube ... Primary Periton... Uterine Cancer Cervical Cancer Gynecologic Can... | SIGNAL | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | NCT01243762 | Neoplasms Malig... | dalotuzumab MK-0752 ridaforolimus MK-2206 | 18 Years - | Merck Sharp & Dohme LLC | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
